Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

OBJECTIVE: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20–30 mg/kg/d reduces iron b...

Descripción completa

Detalles Bibliográficos
Autores principales: Taher, Ali, El-Beshlawy, Amal, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Hmissi, Abdel, Al Jefri, Abdullah
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730551/
https://www.ncbi.nlm.nih.gov/pubmed/19187278
http://dx.doi.org/10.1111/j.1600-0609.2009.01228.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730551/
https://www.ncbi.nlm.nih.gov/pubmed/19187278
http://dx.doi.org/10.1111/j.1600-0609.2009.01228.x

Ejemplares similares